Patients affected by tumors with EGFR mutations have experienced a revolution in treatment landscape due to osimertinib, a very effective precision medicine for lung cancer of non-small cell type (NSCLC).the selective inhibitory power of osimertinib the epidermal growth factor receptor (EGFR) tyrosine kinase, thereby decelerating tumor progression and extending lifespan, contributes to its success.in everyday medical use, locating suitable biomarkers for forecasting responsiveness and resistance to osimertinib remains a critical challenge.This article aims to delve into the function of osimertinib biomarkers in tailoring treatments for individuals with lung cancer.The main…
